Male Infertility Market Analysis By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay), By Treatment, And Segment Forecasts, 2014 - 2025

The global male infertility market is expected to reach USD 4.7 billion by 2025, according to a new report by Grand View Research, Inc. Globally, increasing infertility in male and advancements in diagnostic tests have been major factors driving the market growth. In addition, growing consciousness regarding factors causing male infertility and Assisted Reproductive Technology (ART) has led to increased adoption of treatment.
Furthermore, increasing aging population, rising obesity, and other lifestyle-associated diseases causing infertility are likely to boost the market during the forecast period. In the U.S., one third of infertility cases are due to female factor, one third due to male factors, and remaining one third are unexplained.
DNA fragmentation technique was the largest segment in male infertility tests market in 2016 and is expected to maintain its dominance during the forecast period due to rapid growth in next few years. High cost and increasing adoption in developed countries due to higher sensitivity and reliable analysis of sperm DNA integrity are the key factors for its dominance.
In 2016, ART segment dominated in the treatment market due to high success rate. In Vitro Fertilization and Intracytoplasmic Sperm Injection (ICSI) are the major ARTs used. Medications include corticosteroids and hormonal therapy; however, they are effective in very few cases. Hence, low demand, less adherence, and lower cost as compared to ART are likely to slow the growth of the medication market.
Further Key Findings From the Report Suggest:
‧ Rising demand of ARTs across the globe is expected to propel growth at the fastest rate from 2017 to 2025
‧ DNA fragmentation technique for the testing of male infertility dominated in 2016 and is estimated to generate revenue at a rapid rate over the forecast period.
‧ Oxidative stress analysis is another method gaining popularity due to accurate determination of reactive oxygen species. The test accounted second largest share in the testing market.
‧ The Europe market was the largest in 2016 and is expected to maintain its dominance during forecast period due to higher awareness, strong diagnosis rate, and high adoption of costlier treatment.
‧ The industry in Asia Pacific is projected to witness substantial growth over the next decade owing to growing investment by several clinics and pharmaceutical companies in the region, and increasing healthcare expenditure.
‧ Some key players include EMD Sereno, Inc.; Aytu BioScience, Inc.; Bayer Healthcare; Cadila Healthcare Ltd.; Intas Pharmaceuticals Ltd.; Halotech DNA SL; SCSA diagnostics, Inc.; and Andrology Solutions. However, EMD Sereno, Inc. currently dominates the male infertility market.

Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Male Infertility Industry Outlook
3.1. Market segmentation
3.2. Market size and growth prospects, 2014 - 2025
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key Opportunities Prioritized
3.5. Industry Analysis - Porter's
3.6. PESTEL Analysis, 2015
3.7. Male Infertility Competitive Scenario, 2016
3.7.1. Competitive landscape: Market position analysis (based on product portfolio, regional presence and strategic initiatives)
Chapter 4. Male Infertility Market: Test Outlook
4.1. Male Infertility Market Share by Test, 2016 & 2025 (USD Million)
4.2. DNA Fragmentation Technique
4.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.2.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
4.3. Oxidative Stress Analysis
4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.3.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
4.4. Microscopic Examination
4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.4.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
4.5. Sperm Agglutination
4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.5.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
4.6. Computer-Assisted Semen Analysis
4.6.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.6.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
4.7. Sperm Penetration Assay
4.7.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.7.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
4.8. Others
4.8.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.8.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
Chapter 5. Male Infertility Market: Treatment Outlook
5.1. Male Infertility Market Share by Treatment, 2016 & 2025 (USD Million)
5.2. Assisted Reproductive Technology (ART)
5.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.2.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
5.3. Medication
5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.3.2. Market estimates and forecast by region, 2014 - 2025 (USD Million)
Chapter 6. Male Infertility Market: Regional Outlook
6.1. Male Infertility Market Share by Region, 2016 & 2025 (USD Million)
6.2. North America
6.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.2.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.2.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.2.4. U.S.
6.2.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.2.4.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.2.4.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.2.5. Canada
6.2.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.2.5.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.2.5.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.3. Europe
6.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.3.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.3.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.3.4. Germany
6.3.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.3.4.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.3.4.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.3.5. U.K.
6.3.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.3.5.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.3.5.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.4. Asia Pacific
6.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.4.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.4.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.4.4. China
6.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.4.4.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.4.4.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.4.5. Japan
6.4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.4.5.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.4.5.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.5. Central & South America
6.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.5.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.5.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.5.4. Brazil
6.5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.5.4.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.5.4.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.5.5. Mexico
6.5.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.5.5.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.5.5.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.6. Middle East & Africa
6.6.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.6.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.6.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
6.6.4. South Africa
6.6.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
6.6.4.2. Market estimates and forecast by test, 2014 - 2025 (USD Million)
6.6.4.3. Market estimates and forecast by treatment, 2014 - 2025 (USD Million)
Chapter 7. Competitive Landscape
7.1. Competitive Environment
7.2. Strategy Framework
Chapter 8. Company Profiles
8.1. EMD Sereno, Inc.
8.1.1. Company overview
8.1.2. Financial performance
8.1.3. Industries and services catered
8.1.4. Product benchmarking
8.1.5. Strategic initiatives
8.2. Endo International plc
8.2.1. Company overview
8.2.2. Financial performance
8.2.3. Industries and services catered
8.2.4. Product benchmarking
8.2.5. Strategic initiatives
8.3. Sanofi
8.3.1. Company overview
8.3.2. Financial performance
8.3.3. Industries and services catered
8.3.4. Product benchmarking
8.3.5. Strategic initiatives
8.4. Bayer Group
8.4.1. Company overview
8.4.2. Financial performance
8.4.3. Industries and services catered
8.4.4. Product benchmarking
8.4.5. Strategic initiatives
8.5. SCSA Diagnostics, Inc.
8.5.1. Company overview
8.5.2. Financial performance
8.5.3. Industries and services catered
8.5.4. Product benchmarking
8.5.5. Strategic initiatives
8.6. Andrology Solutions
8.6.1. Company overview
8.6.2. Financial performance
8.6.3. Industries and services catered
8.6.4. Product benchmarking
8.6.5. Strategic initiatives
8.7. Halotech DNA SL
8.7.1. Company overview
8.7.2. Financial performance
8.7.3. Industries and services catered
8.7.4. Product benchmarking
8.7.5. Strategic initiatives
8.8. Intas Pharmaceuticals Ltd.
8.8.1. Company overview
8.8.2. Financial performance
8.8.3. Industries and services catered
8.8.4. Product benchmarking
8.8.5. Strategic initiatives
8.9. Aytu BioScience, Inc.
8.9.1. Company overview
8.9.2. Financial performance
8.9.3. Industries and services catered
8.9.4. Product benchmarking
8.9.5. Strategic initiatives
8.10. Cadila Healthcare Ltd.
8.10.1. Company overview
8.10.2. Financial performance
8.10.3. Industries and services catered
8.10.4. Product benchmarking
8.10.5. Strategic initiatives